# Study of Intravenous NRX-1074 in Patients With Major Depressive Disorder

> **NCT02067793** · PHASE2 · COMPLETED · sponsor: **Naurex, Inc, an affiliate of Allergan plc** · enrollment: 151 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** NRX-1074 1 mg
- **DRUG:** Placebo
- **DRUG:** NRX-1074 5 mg
- **DRUG:** NRX-1074 10 mg

## Key facts

- **NCT ID:** NCT02067793
- **Lead sponsor:** Naurex, Inc, an affiliate of Allergan plc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2015-02
- **Final completion:** 2015-02
- **Target enrollment:** 151 (ACTUAL)
- **Last updated:** 2016-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02067793

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02067793, "Study of Intravenous NRX-1074 in Patients With Major Depressive Disorder". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02067793. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*